ID   ALPK1_HUMAN             Reviewed;        1244 AA.
AC   Q96QP1; B4E3G1; F5H138; Q68CI9; Q6P9F9; Q6ZNK4; Q9P201;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   12-OCT-2022, entry version 153.
DE   RecName: Full=Alpha-protein kinase 1 {ECO:0000303|PubMed:30111836};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:27169898, ECO:0000269|PubMed:30111836};
DE   AltName: Full=Chromosome 4 kinase {ECO:0000303|PubMed:10021370};
DE   AltName: Full=Lymphocyte alpha-protein kinase {ECO:0000312|HGNC:HGNC:20917};
GN   Name=ALPK1 {ECO:0000303|PubMed:30111836, ECO:0000312|HGNC:HGNC:20917};
GN   Synonyms=KIAA1527 {ECO:0000303|PubMed:10819331}, LAK
GN   {ECO:0000312|HGNC:HGNC:20917};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-565; ARG-642;
RP   ILE-732 AND THR-861.
RX   PubMed=10021370; DOI=10.1016/s0960-9822(99)80006-2;
RA   Ryazanov A.G., Pavur K.S., Dorovkov M.V.;
RT   "Alpha-kinases: a new class of protein kinases with a novel catalytic
RT   domain.";
RL   Curr. Biol. 9:R43-R45(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS ASP-565;
RP   ARG-642; ASP-681; ILE-732 AND THR-861.
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 77-1244 (ISOFORM 1), AND VARIANTS
RP   ASP-565; ARG-642; ILE-732 AND THR-861.
RC   TISSUE=Spleen;
RA   Jikuya H., Takano J., Kikuno R., Nagase T., Ohara O.;
RT   "The nucleotide sequence of a long cDNA clone isolated from human spleen.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 444-1244 (ISOFORM 1), VARIANTS
RP   ASP-565; ARG-642; ILE-732 AND THR-861, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=10819331; DOI=10.1093/dnares/7.2.143;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:143-150(2000).
RN   [7]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1018-1244 (ISOFORM 1).
RX   PubMed=15221005; DOI=10.1038/sj.onc.1207782;
RA   Yamada S., Ohira M., Horie H., Ando K., Takayasu H., Suzuki Y., Sugano S.,
RA   Hirata T., Goto T., Matsunaga T., Hiyama E., Hayashi Y., Ando H., Suita S.,
RA   Kaneko M., Sasaki F., Hashizume K., Ohnuma N., Nakagawara A.;
RT   "Expression profiling and differential screening between hepatoblastomas
RT   and the corresponding normal livers: identification of high expression of
RT   the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.";
RL   Oncogene 23:5901-5911(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=15883161; DOI=10.1074/jbc.m502265200;
RA   Heine M., Cramm-Behrens C.I., Ansari A., Chu H.P., Ryazanov A.G.,
RA   Naim H.Y., Jacob R.;
RT   "Alpha-kinase 1, a new component in apical protein transport.";
RL   J. Biol. Chem. 280:25637-25643(2005).
RN   [10]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=27169898; DOI=10.1038/srep25740;
RA   Lee C.P., Chiang S.L., Ko A.M., Liu Y.F., Ma C., Lu C.Y., Huang C.M.,
RA   Chang J.G., Kuo T.M., Chen C.L., Tsai E.M., Ko Y.C.;
RT   "ALPK1 phosphorylates myosin IIA modulating TNF-alpha trafficking in gout
RT   flares.";
RL   Sci. Rep. 6:25740-25740(2016).
RN   [11]
RP   FUNCTION.
RX   PubMed=28877472; DOI=10.1016/j.celrep.2017.08.039;
RA   Zimmermann S., Pfannkuch L., Al-Zeer M.A., Bartfeld S., Koch M., Liu J.,
RA   Rechner C., Soerensen M., Sokolova O., Zamyatina A., Kosma P.,
RA   Maeurer A.P., Glowinski F., Pleissner K.P., Schmid M., Brinkmann V.,
RA   Karlas A., Naumann M., Rother M., Machuy N., Meyer T.F.;
RT   "ALPK1- and TIFA-dependent innate immune response triggered by the
RT   Helicobacter pylori type IV secretion system.";
RL   Cell Rep. 20:2384-2395(2017).
RN   [12]
RP   FUNCTION.
RX   PubMed=28222186; DOI=10.1371/journal.ppat.1006224;
RA   Milivojevic M., Dangeard A.S., Kasper C.A., Tschon T., Emmenlauer M.,
RA   Pique C., Schnupf P., Guignot J., Arrieumerlou C.;
RT   "ALPK1 controls TIFA/TRAF6-dependent innate immunity against heptose-1,7-
RT   bisphosphate of gram-negative bacteria.";
RL   PLoS Pathog. 13:E1006224-E1006224(2017).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) OF 1-446 IN COMPLEX WITH
RP   ADP-D-GLYCERO-BETA-D-MANNO-HEPTOSE, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF GLN-67; ARG-116;
RP   ARG-150; ARG-153; ASP-231; LYS-233; THR-237; PHE-295 AND LYS-1067.
RX   PubMed=30111836; DOI=10.1038/s41586-018-0433-3;
RA   Zhou P., She Y., Dong N., Li P., He H., Borio A., Wu Q., Lu S., Ding X.,
RA   Cao Y., Xu Y., Gao W., Dong M., Ding J., Wang D.C., Zamyatina A., Shao F.;
RT   "Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-
RT   heptose.";
RL   Nature 561:122-126(2018).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-67; ASP-175; MET-292; MET-320; GLU-339;
RP   GLU-383; ASP-565; ARG-642; LEU-660; ASP-681; ILE-732; THR-861; SER-870;
RP   ILE-873; ASP-910; ASP-916; LEU-935; GLN-1084; PRO-1117 AND GLY-1160.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   VARIANT ROSAH MET-237, INVOLVEMENT IN ROSAH, TISSUE SPECIFICITY, FUNCTION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=30967659; DOI=10.1038/s41436-019-0476-3;
RA   Williams L.B., Javed A., Sabri A., Morgan D.J., Huff C.D., Grigg J.R.,
RA   Heng X.T., Khng A.J., Hollink I.H.I.M., Morrison M.A., Owen L.A.,
RA   Anderson K., Kinard K., Greenlees R., Novacic D., Nida Sen H., Zein W.M.,
RA   Rodgers G.M., Vitale A.T., Haider N.B., Hillmer A.M., Ng P.C., Shankar A.,
RA   Cheng A., Zheng L., Gillies M.C., van Slegtenhorst M., van Hagen P.M.,
RA   Missotten T.O.A.R., Farley G.L., Polo M., Malatack J., Curtin J.,
RA   Martin F., Arbuckle S., Alexander S.I., Chircop M., Davila S., Digre K.B.,
RA   Jamieson R.V., DeAngelis M.M.;
RT   "ALPK1 missense pathogenic variant in five families leads to ROSAH
RT   syndrome, an ocular multisystem autosomal dominant disorder.";
RL   Genet. Med. 21:2103-2115(2019).
RN   [16]
RP   VARIANT ROSAH MET-237, AND INVOLVEMENT IN ROSAH.
RX   PubMed=31939038; DOI=10.1007/s10875-020-00741-6;
RA   Zhong L., Wang J., Wang W., Wang L., Quan M., Tang X., Gou L., Wei M.,
RA   Xiao J., Zhang T., Sui R., Zhou Q., Song H.;
RT   "Juvenile Onset Splenomegaly and Oculopathy Due to Germline Mutation in
RT   ALPK1.";
RL   J. Clin. Immunol. 40:350-358(2020).
CC   -!- FUNCTION: Serine/threonine-protein kinase that detects bacterial
CC       pathogen-associated molecular pattern metabolites (PAMPs) and initiates
CC       an innate immune response, a critical step for pathogen elimination and
CC       engagement of adaptive immunity (PubMed:28877472, PubMed:28222186,
CC       PubMed:30111836). Specifically recognizes and binds ADP-D-glycero-beta-
CC       D-manno-heptose (ADP-Heptose), a potent PAMP present in all Gram-
CC       negative and some Gram-positive bacteria (PubMed:30111836). ADP-
CC       Heptose-binding stimulates its kinase activity to phosphorylate and
CC       activate TIFA, triggering pro-inflammatory NF-kappa-B signaling
CC       (PubMed:30111836). May be involved in monosodium urate monohydrate
CC       (MSU)-induced inflammation by mediating phosphorylation of
CC       unconventional myosin MYO9A (PubMed:27169898). May also play a role in
CC       apical protein transport by mediating phosphorylation of unconventional
CC       myosin MYO1A (PubMed:15883161). May play a role in ciliogenesis
CC       (PubMed:30967659). {ECO:0000269|PubMed:15883161,
CC       ECO:0000269|PubMed:27169898, ECO:0000269|PubMed:28222186,
CC       ECO:0000269|PubMed:28877472, ECO:0000269|PubMed:30111836,
CC       ECO:0000269|PubMed:30967659}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:27169898, ECO:0000269|PubMed:30111836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:27169898,
CC         ECO:0000269|PubMed:30111836};
CC   -!- ACTIVITY REGULATION: Serine/threonine-protein kinase activity is
CC       stimulated upon ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose)-
CC       binding. {ECO:0000269|PubMed:30111836}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:30111836}.
CC       Cytoplasm, cytoskeleton, spindle pole {ECO:0000269|PubMed:30967659}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:30967659}. Cell projection, cilium
CC       {ECO:0000269|PubMed:30967659}. Note=Localized at the base of primary
CC       cilia. {ECO:0000269|PubMed:30967659}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96QP1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96QP1-2; Sequence=VSP_044735;
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver. Expressed in the optic
CC       nerve and retinal pigmented epithelium. Lower expression is observed in
CC       the macula and extramacular retina (PubMed:30967659).
CC       {ECO:0000269|PubMed:10819331, ECO:0000269|PubMed:30967659}.
CC   -!- DISEASE: Retinal dystrophy, optic nerve edema, splenomegaly,
CC       anhidrosis, and migraine headache syndrome (ROSAH) [MIM:614979]: An
CC       autosomal dominant disorder characterized by decreased vision
CC       associated with optic nerve edema, evident in childhood. Low-grade
CC       ocular inflammation is common in affected individuals. Later in
CC       childhood or the second decade of life, patients have increasing visual
CC       impairment, abnormal cone function and loss of rod function. By the
CC       third decade of life, visual acuity ranges from counting fingers to no
CC       light perception. Patients also show anhidrosis, splenomegaly, mild
CC       pancytopenia, and most experience headaches that may be migraine-like
CC       in nature. {ECO:0000269|PubMed:30967659, ECO:0000269|PubMed:31939038}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Alpha-type
CC       protein kinase family. ALPK subfamily. {ECO:0000305}.
CC   -!- CAUTION: D-glycero-beta-D-manno-heptose 1,7-bisphosphate (HBP) was
CC       initially thought to constitute the bacterial pathogen-associated
CC       molecular pattern metabolite (PAMP) triggering the ALPK1-TIFA innate
CC       immunune response (PubMed:28877472, PubMed:28222186). It was however
CC       shown that ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose) constitutes
CC       the main PAMP that activates the kinase activity of ALPK1
CC       (PubMed:30111836). {ECO:0000269|PubMed:28222186,
CC       ECO:0000269|PubMed:28877472, ECO:0000269|PubMed:30111836}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC85140.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAC85140.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAC85140.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC       Sequence=BC060780; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY044164; AAK94675.1; -; mRNA.
DR   EMBL; AK304708; BAG65473.1; -; mRNA.
DR   EMBL; AC004049; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC109347; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC060780; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK131090; BAC85140.1; ALT_SEQ; mRNA.
DR   EMBL; AB040960; BAA96051.1; -; mRNA.
DR   EMBL; AB075877; BAD38659.1; -; mRNA.
DR   CCDS; CCDS3697.1; -. [Q96QP1-1]
DR   CCDS; CCDS58923.1; -. [Q96QP1-2]
DR   RefSeq; NP_001095876.1; NM_001102406.1. [Q96QP1-1]
DR   RefSeq; NP_001240813.1; NM_001253884.1. [Q96QP1-2]
DR   RefSeq; NP_079420.3; NM_025144.3. [Q96QP1-1]
DR   PDB; 5Z2C; X-ray; 2.59 A; A/B/C/D/E/F/G/H/I=1-446.
DR   PDBsum; 5Z2C; -.
DR   AlphaFoldDB; Q96QP1; -.
DR   SMR; Q96QP1; -.
DR   BioGRID; 123183; 9.
DR   IntAct; Q96QP1; 3.
DR   STRING; 9606.ENSP00000398048; -.
DR   iPTMnet; Q96QP1; -.
DR   PhosphoSitePlus; Q96QP1; -.
DR   BioMuta; ALPK1; -.
DR   DMDM; 308153632; -.
DR   EPD; Q96QP1; -.
DR   MassIVE; Q96QP1; -.
DR   MaxQB; Q96QP1; -.
DR   PaxDb; Q96QP1; -.
DR   PeptideAtlas; Q96QP1; -.
DR   PRIDE; Q96QP1; -.
DR   ProteomicsDB; 25531; -.
DR   ProteomicsDB; 77886; -. [Q96QP1-1]
DR   Antibodypedia; 26436; 101 antibodies from 23 providers.
DR   DNASU; 80216; -.
DR   Ensembl; ENST00000177648.13; ENSP00000177648.9; ENSG00000073331.18. [Q96QP1-1]
DR   Ensembl; ENST00000458497.6; ENSP00000398048.1; ENSG00000073331.18. [Q96QP1-1]
DR   Ensembl; ENST00000504176.6; ENSP00000426044.2; ENSG00000073331.18. [Q96QP1-2]
DR   Ensembl; ENST00000650871.1; ENSP00000498374.1; ENSG00000073331.18. [Q96QP1-1]
DR   GeneID; 80216; -.
DR   KEGG; hsa:80216; -.
DR   MANE-Select; ENST00000650871.1; ENSP00000498374.1; NM_025144.4; NP_079420.3.
DR   UCSC; uc003ian.5; human. [Q96QP1-1]
DR   CTD; 80216; -.
DR   DisGeNET; 80216; -.
DR   GeneCards; ALPK1; -.
DR   HGNC; HGNC:20917; ALPK1.
DR   HPA; ENSG00000073331; Low tissue specificity.
DR   MalaCards; ALPK1; -.
DR   MIM; 607347; gene.
DR   MIM; 614979; phenotype.
DR   neXtProt; NX_Q96QP1; -.
DR   OpenTargets; ENSG00000073331; -.
DR   Orphanet; 313800; Retinal dystrophy-optic nerve edema-splenomegaly-anhidrosis-migraine headache syndrome.
DR   PharmGKB; PA134891785; -.
DR   VEuPathDB; HostDB:ENSG00000073331; -.
DR   eggNOG; ENOG502QX1X; Eukaryota.
DR   GeneTree; ENSGT00940000159753; -.
DR   HOGENOM; CLU_007421_0_0_1; -.
DR   InParanoid; Q96QP1; -.
DR   OMA; KCNEICH; -.
DR   PhylomeDB; Q96QP1; -.
DR   TreeFam; TF316085; -.
DR   PathwayCommons; Q96QP1; -.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-9645460; Alpha-protein kinase 1 signaling pathway.
DR   SignaLink; Q96QP1; -.
DR   BioGRID-ORCS; 80216; 8 hits in 1076 CRISPR screens.
DR   ChiTaRS; ALPK1; human.
DR   GeneWiki; ALPK1; -.
DR   GenomeRNAi; 80216; -.
DR   Pharos; Q96QP1; Tbio.
DR   PRO; PR:Q96QP1; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q96QP1; protein.
DR   Bgee; ENSG00000073331; Expressed in buccal mucosa cell and 173 other tissues.
DR   ExpressionAtlas; Q96QP1; baseline and differential.
DR   Genevisible; Q96QP1; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005929; C:cilium; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0048029; F:monosaccharide binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0060271; P:cilium assembly; IMP:UniProtKB.
DR   GO; GO:0002753; P:cytoplasmic pattern recognition receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   InterPro; IPR043529; ALPK1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR004166; MHCK_EF2_kinase.
DR   PANTHER; PTHR46747; PTHR46747; 1.
DR   Pfam; PF02816; Alpha_kinase; 1.
DR   SMART; SM00811; Alpha_kinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51158; ALPHA_KINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell projection;
KW   Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; Disease variant;
KW   Immunity; Innate immunity; Kinase; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..1244
FT                   /note="Alpha-protein kinase 1"
FT                   /id="PRO_0000260028"
FT   DOMAIN          1017..1237
FT                   /note="Alpha-type protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00501"
FT   REGION          650..675
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          701..737
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          757..798
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          824..848
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        703..733
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         61
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   BINDING         67
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   BINDING         116
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   BINDING         150..153
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   BINDING         231
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   BINDING         233
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   BINDING         236..237
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   BINDING         295
FT                   /ligand="ADP-D-glycero-beta-D-manno-heptose"
FT                   /ligand_id="ChEBI:CHEBI:59967"
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   VAR_SEQ         1..92
FT                   /note="MNNQKVVAVLLQECKQVLDQLLLEAPDVSEEDKSEDQRCRALLPSELRTLIQ
FT                   EAKEMKWPFVPEKWQYKQAVGPEDKTNLKDVIGAGLQQLL -> MCRKRTRARTSAAE
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044735"
FT   VARIANT         67
FT                   /note="Q -> R (in dbSNP:rs33943680)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041511"
FT   VARIANT         175
FT                   /note="N -> D (in dbSNP:rs6533616)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_028982"
FT   VARIANT         237
FT                   /note="T -> M (in ROSAH)"
FT                   /evidence="ECO:0000269|PubMed:30967659,
FT                   ECO:0000269|PubMed:31939038"
FT                   /id="VAR_084993"
FT   VARIANT         292
FT                   /note="T -> M (in dbSNP:rs34120296)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041512"
FT   VARIANT         320
FT                   /note="L -> M (in dbSNP:rs757602009)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041513"
FT   VARIANT         339
FT                   /note="K -> E (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041514"
FT   VARIANT         383
FT                   /note="K -> E (in dbSNP:rs147641444)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041515"
FT   VARIANT         565
FT                   /note="G -> D (in dbSNP:rs2074388)"
FT                   /evidence="ECO:0000269|PubMed:10021370,
FT                   ECO:0000269|PubMed:10819331, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|Ref.5"
FT                   /id="VAR_028983"
FT   VARIANT         642
FT                   /note="H -> R (in dbSNP:rs13148353)"
FT                   /evidence="ECO:0000269|PubMed:10021370,
FT                   ECO:0000269|PubMed:10819331, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|Ref.5"
FT                   /id="VAR_028984"
FT   VARIANT         660
FT                   /note="P -> L (in dbSNP:rs35389530)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041516"
FT   VARIANT         681
FT                   /note="G -> D (in dbSNP:rs35519493)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041517"
FT   VARIANT         732
FT                   /note="M -> I (in dbSNP:rs2074379)"
FT                   /evidence="ECO:0000269|PubMed:10021370,
FT                   ECO:0000269|PubMed:10819331, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|Ref.5"
FT                   /id="VAR_028985"
FT   VARIANT         861
FT                   /note="M -> T (in dbSNP:rs11726117)"
FT                   /evidence="ECO:0000269|PubMed:10021370,
FT                   ECO:0000269|PubMed:10819331, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|Ref.5"
FT                   /id="VAR_028986"
FT   VARIANT         870
FT                   /note="G -> S (in dbSNP:rs2074380)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_028987"
FT   VARIANT         873
FT                   /note="R -> I (in dbSNP:rs34946272)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041518"
FT   VARIANT         910
FT                   /note="E -> D (in dbSNP:rs35308602)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041519"
FT   VARIANT         916
FT                   /note="N -> D (in dbSNP:rs2074381)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_028988"
FT   VARIANT         935
FT                   /note="P -> L (in dbSNP:rs34780600)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041520"
FT   VARIANT         1008
FT                   /note="H -> P (in dbSNP:rs34079946)"
FT                   /id="VAR_057741"
FT   VARIANT         1084
FT                   /note="R -> Q (in dbSNP:rs34677416)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041521"
FT   VARIANT         1117
FT                   /note="L -> P (in dbSNP:rs35756863)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041522"
FT   VARIANT         1160
FT                   /note="A -> G (in dbSNP:rs55696324)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041523"
FT   MUTAGEN         67
FT                   /note="Q->A: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity; when
FT                   associated with A-231."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         116
FT                   /note="R->A: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         150
FT                   /note="R->A: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         153
FT                   /note="R->A: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         231
FT                   /note="D->A: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity; when
FT                   associated with A-67."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         233
FT                   /note="K->A: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         237
FT                   /note="T->E: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity; when
FT                   associated with K-295."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         295
FT                   /note="F->K: Impaired
FT                   ADP-D-glycero-beta-D-manno-heptose-binding and ability to
FT                   activate the serine/threonine-protein kinase activity; when
FT                   associated with E-237."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   MUTAGEN         1067
FT                   /note="K->M: Abolishes the serine/threonine-protein kinase
FT                   and ability to initiate the innate immune response."
FT                   /evidence="ECO:0000269|PubMed:30111836"
FT   CONFLICT        83
FT                   /note="V -> L (in Ref. 5; BAC85140)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        577
FT                   /note="S -> G (in Ref. 2; BAG65473)"
FT                   /evidence="ECO:0000305"
FT   HELIX           4..23
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           30..41
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           45..55
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   TURN            65..67
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           74..76
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           80..86
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           88..100
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           104..120
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           124..137
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           145..157
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           161..173
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   TURN            174..176
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   STRAND          184..186
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           187..206
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           210..225
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   STRAND          227..229
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           232..248
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           251..258
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           266..270
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           274..288
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   TURN            289..291
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           293..311
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           318..337
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           348..369
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           373..394
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           398..418
FT                   /evidence="ECO:0007829|PDB:5Z2C"
FT   HELIX           442..444
FT                   /evidence="ECO:0007829|PDB:5Z2C"
SQ   SEQUENCE   1244 AA;  138861 MW;  857D353D159A1630 CRC64;
     MNNQKVVAVL LQECKQVLDQ LLLEAPDVSE EDKSEDQRCR ALLPSELRTL IQEAKEMKWP
     FVPEKWQYKQ AVGPEDKTNL KDVIGAGLQQ LLASLRASIL ARDCAAAAAI VFLVDRFLYG
     LDVSGKLLQV AKGLHKLQPA TPIAPQVVIR QARISVNSGK LLKAEYILSS LISNNGATGT
     WLYRNESDKV LVQSVCIQIR GQILQKLGMW YEAAELIWAS IVGYLALPQP DKKGLSTSLG
     ILADIFVSMS KNDYEKFKNN PQINLSLLKE FDHHLLSAAE ACKLAAAFSA YTPLFVLTAV
     NIRGTCLLSY SSSNDCPPEL KNLHLCEAKE AFEIGLLTKR DDEPVTGKQE LHSFVKAAFG
     LTTVHRRLHG ETGTVHAASQ LCKEAMGKLY NFSTSSRSQD REALSQEVMS VIAQVKEHLQ
     VQSFSNVDDR SYVPESFECR LDKLILHGQG DFQKILDTYS QHHTSVCEVF ESDCGNNKNE
     QKDAKTGVCI TALKTEIKNI DTVSTTQEKP HCQRDTGISS SLMGKNVQRE LRRGGRRNWT
     HSDAFRVSLD QDVETETEPS DYSNGEGAVF NKSLSGSQTS SAWSNLSGFS SSASWEEVNY
     HVDDRSARKE PGKEHLVDTQ CSTALSEELE NDREGRAMHS LHSQLHDLSL QEPNNDNLEP
     SQNQPQQQMP LTPFSPHNTP GIFLAPGAGL LEGAPEGIQE VRNMGPRNTS AHSRPSYRSA
     SWSSDSGRPK NMGTHPSVQK EEAFEIIVEF PETNCDVKDR QGKEQGEEIS ERGAGPTFKA
     SPSWVDPEGE TAESTEDAPL DFHRVLHNSL GNISMLPCSS FTPNWPVQNP DSRKSGGPVA
     EQGIDPDAST VDEEGQLLDS MDVPCTNGHG SHRLCILRQP PGQRAETPNS SVSGNILFPV
     LSEDCTTTEE GNQPGNMLNC SQNSSSSSVW WLKSPAFSSG SSEGDSPWSY LNSSGSSWVS
     LPGKMRKEIL EARTLQPDDF EKLLAGVRHD WLFQRLENTG VFKPSQLHRA HSALLLKYSK
     KSELWTAQET IVYLGDYLTV KKKGRQRNAF WVHHLHQEEI LGRYVGKDYK EQKGLWHHFT
     DVERQMTAQH YVTEFNKRLY EQNIPTQIFY IPSTILLILE DKTIKGCISV EPYILGEFVK
     LSNNTKVVKT EYKATEYGLA YGHFSYEFSN HRDVVVDLQG WVTGNGKGLI YLTDPQIHSV
     DQKVFTTNFG KRGIFYFFNN QHVECNEICH RLSLTRPSME KPCT
//
